Colgate-Palmolive (NYSE:CL) PT Lowered to $110.00 at TD Cowen

Colgate-Palmolive (NYSE:CL) had its price objective dropped by TD Cowen from $115.00 to $110.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s target price would suggest a potential upside of 16.16% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Stifel Nicolaus cut Colgate-Palmolive from a “buy” rating to a “hold” rating and lowered their price target for the stock from $105.00 to $101.00 in a research report on Monday. UBS Group lifted their price target on Colgate-Palmolive from $119.00 to $122.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Wells Fargo & Company cut Colgate-Palmolive from an “equal weight” rating to an “underweight” rating and set a $100.00 price target for the company. in a research report on Monday, September 16th. Citigroup boosted their price objective on Colgate-Palmolive from $103.00 to $112.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Finally, Jefferies Financial Group downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating and lowered their target price for the stock from $103.00 to $95.00 in a research note on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.53.

Colgate-Palmolive Stock Down 1.0 %

Shares of CL stock opened at $94.70 on Monday. Colgate-Palmolive has a 1-year low of $72.36 and a 1-year high of $109.30. The stock’s fifty day moving average price is $103.15 and its 200 day moving average price is $98.06. The company has a debt-to-equity ratio of 16.90, a current ratio of 1.06 and a quick ratio of 0.70. The company has a market cap of $77.70 billion, a price-to-earnings ratio of 29.91, a price-to-earnings-growth ratio of 3.54 and a beta of 0.40.

Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.87 by $0.04. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $5 billion. During the same period in the previous year, the business earned $0.77 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. On average, research analysts expect that Colgate-Palmolive will post 3.57 earnings per share for the current fiscal year.

Insider Transactions at Colgate-Palmolive

In other news, Director Martina Hundmejean sold 2,313 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $103.86, for a total transaction of $240,228.18. Following the completion of the transaction, the director now directly owns 11,755 shares in the company, valued at $1,220,874.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Sally Massey sold 15,850 shares of Colgate-Palmolive stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total value of $1,636,988.00. Following the completion of the transaction, the insider now directly owns 13,942 shares in the company, valued at approximately $1,439,929.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Martina Hundmejean sold 2,313 shares of Colgate-Palmolive stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $103.86, for a total value of $240,228.18. Following the completion of the transaction, the director now owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,490 shares of company stock worth $4,486,063 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. E Fund Management Hong Kong Co. Ltd. acquired a new stake in Colgate-Palmolive in the second quarter valued at $25,000. Continuum Advisory LLC raised its stake in Colgate-Palmolive by 46.5% in the second quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after buying an additional 125 shares in the last quarter. Gradient Investments LLC raised its stake in Colgate-Palmolive by 150.4% in the second quarter. Gradient Investments LLC now owns 666 shares of the company’s stock valued at $65,000 after buying an additional 400 shares in the last quarter. Financial Connections Group Inc. acquired a new stake in Colgate-Palmolive in the second quarter valued at $68,000. Finally, Triad Wealth Partners LLC acquired a new stake in Colgate-Palmolive in the second quarter valued at $71,000. 80.41% of the stock is currently owned by hedge funds and other institutional investors.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.